Tamoxifen

Endocrine-Related Cancer

Volumn 4, Issue 3, 1997, Pages 237-243

  Baum, M ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

TAMOXIFEN;

BREAST CANCER; FEMALE; HUMAN; SHORT SURVEY;

EID: 0030814273     PISSN: 13510088     EISSN: None     Source Type: Journal    
DOI: 10.1677/erc.0.0040237     Document Type: Short Survey

References (35)

1. Abram P, Ahern R, Baum M, Berstock D, Cawthorn S, Coibion M, Fennessy M, Houghton J, Kissin M, Lee D, MacRae K, Moritz S, Odling-Smee W, Perry M, Riley D, Saunders C, Sauven P, Smith I, Tobias J et al. 1996 Preliminary results from the Cancer Research Campaign trial evaluating tamoxifen duration in women aged fifty years or older with breast cancer. Journal of the National Cancer Institute 88 1834-1839.
2. BCTC (Breast Cancer Trials Committee) 1987 Adjuvant tamoxifen in the management of operable breast cancer: the Scottish Trial. Report from the Breast Cancer Trials Committee, Scottish Cancer Trials Office (MRC) Edinburgh. Lance 12 171-175.
3. Beral V, Hermon C, Reeves G & Peto R 1995 Sudden fall in breast cancer death rates in England and Wales. Lancet 345 1642-1643.
4. Bulbrook RD 1996 Long term adjuvant therapy for primary breast cancer. British Medical Journal 312 389-390.
5. Carbone PP & Davis TE 1978 Medical treatment for advanced breast cancer. Seminars in Oncology 5417-427.
6. Chang J, Powles TJ, Ashley SE, Gregory RK, Tidy VA, Treleaven JG & Singh R 1996 The effect of tamoxifen and hormone replacement therapy on serum cholesterol, bone mineral density and coagulation factors in healthy postmenopausal women participating in a randomised controlled tamoxifen prevention study. Annals of Oncology 7 671-675.
7. Cole MP, Jones CT & Todd ID 1971 A new anti-oestrogenic agent in late breast cancer. An early clinical appraisal of ICI46474. British Journal of Cancer 25 270-275.
8. Colletta AA, Wakefield LM, Howell FV, van-Roozendaal KE, Danielpour D, Ebbs SR, Sporn MB & Baum M 1990 Anti-oestrogens induce the secretion of active transforming growth factor beta from human fetal fibroblasts. British Journal of Cancer 62 405-409.
9. Colleta AA, Benson JR & Baum M 1994 Alternate mechanisms of action of Tamoxifen. Breast Cancer Research and Treatment 31 5-9.
10. Cuzick J & Baum M 1985 Tamoxifen and contralateral breast cancer. Lancet 2 282.
11. EBCTCG (Early Breast Cancer Trialists' Collaborative Group) 1988 Effects of adjuvant tamoxifen and of cytotoxic therapy on mortality in early breast cancer. An overview of 61 randomized trials among 28,896 women. New England Journal of Medicine 319 1681-1692.
12. EBCTCG (Early Breast Cancer Trialists' Collaborative Group) 1992 Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy. 133 randomised trials involving 31,000 recurrences and 24,000 deaths among 75,000 women. Lancet 339 1-15, 71-85.
13. Fisher B, Constatino JP, Redmond CK, Fisher ER, Wickerham DL, Cronin WM, Bowman D, Couture J, Dimitrov NV, Evans J, Farrar W, Kavanah M, Lickley HL, Margolese R, Paterson AHG, Robidoux A, Shibata H & Terz J 1994 Endometrial cancer in tamoxifen treated breast cancer patients: findings from the National Adjuvant Breast and Bowel Project. Journal of the National Cancer Institute 86 527-537.
14. Fisher B, Dignam J, Bryant J, DeCillis A, Wickerham DL, Wolmark N, Costantino J, Redmond C, Fisher ER, Bowman DM, Deschenes L, Dimitrov NV, Margolese RG, Robidoux A, Shibata H, Terz J, Paterson AH, Feldman MI, Farrar W, Evans J & Lickley HL 1996 Five versus more than five years of tamoxifen therapy for breast cancer patients with negative lymph nodes and estrogen receptor-positive tumors. Journal of the National Cancer Institute 88 1529-1542.
15. Fornander T, Rutqvist LE, Cedermark B, Glas U, Mattsson A, Silfversward D, Skoog L, Somell A, Theve T, Wilking N et al. 1989 Adjuvant tamoxifen in early breast cancer, occurrence of new primary cancers. Lancet 1 117-120.
16. Fromson JM, Pearson S & Bramah S 1973 The metabolism of tamoxifen (ICI46,474). I - In laboratory animals and II - In female patients. Xenobiotica 3 693-714.
17. Gagliardi A & Collins DC 1993 Inhibition of angiogenesis by antiestrogens. Cancer Research 53 533-535.
18. Harper MJ & Walpole AL 1966 Contrasting endocrine activities of cis and trans isomers in a series of substituted triphenylethylenes. Nature 212 87.
19. Harper MJ & Walpole AL 1967a Mode of action of ICI 46,474 in preventing implantation in rats. Journal of Endocrinology 37 83-92.
20. Harper MJ & Walpole AL 1967b A new derivative of triphenylethylene: effect on implantation and mode of action in rats. Journal of Reproduction and Fertility 13 101-119.
21. Huynh HT, Tetenes F, Wallace L & Pollak M 1993 In vivo inhibition of insulin-like growth factor I gene expression by tamoxifen. Cancer Research 53 1727-1730.
22. Kang Y, Cortina R & Perry RR 1996 Role of c-myc in tamoxifen-induced apoptosis estrogen-independent breast cancer cells. Journal of the National Cancer Institute 88 279-284.
23. Lahti E, Blanco G, Kauppila A, Apaja Sarkkinen M, Taskinen PJ & Laatikainen T 1993 Endometrial changes in postmenopausal breast cancer patients receiving tamoxifen. Obstetrics and Gynecology 81 660-664.
24. Love R, Mazess RB, Barden HS et al. 1991. Effects of tamoxifen on bone mineral density in postmenopausal - women with breast cancer. Annals of Internal Medicine 115 860-864.
25. McDonald CC & Stewart HJ (the Scottish Breast Cancer Committee) 1991 Fatal myocardial infarction in the Scottish adjuvant tamoxifen trial. British Medical Journal 303 435-437.
26. NATO (Nolvadex Adjuvant Trial Organisation) 1983 Controlled trial of tamoxifen as adjuvant agent in management of early breast cancer. Interim analysis at four years by Nolvadex Adjuvant Trial Organisation. Lancet 1257-261.
27. Rose C, Thorpe SM, Andersen KW, Pedersen BV, Mouridsen HT, Blichert-Toft M & Rasmussen BB 1985 Beneficial effect of adjuvant tamoxifen therapy in primary breast cancer patients with high oestrogen receptor values. Lancet 1 16-19.
28. Rutqvist LE, Cedermark B, Glas U, Johansson H, Nordenskojold B, Skoog L, Somell A, Theve T, Fribert S & Askergren J 1987 The Stockholm trial on adjuvant tamoxifen in early breast cancer. Correlation between estrogen receptor level and treatment effect. Breast Cancer Research and Treatment 10 255-266.
29. Rutqvist LE, Cedermark B, Glas U, Mattsson A, Skoog L, Somell A, Theve T, Wilking N, Askergren J, Hjalmar ML et al. 1991 Contralateral primary tumors in breast cancer patients in a randomized trial of adjuvant tamoxifen therapy. Journal of the National Cancer Institute 83 1299-1306.
30. SBCCG (Swedish Breast Cancer Cooperative Group) (Rutqvist LE, Hatschek T, Ryden S, Bergh J, Bengtsson NO, Carstenssen J, Nordenskjold B, Wallgren A, Aspergren K, Bergljung L, Borg A, Idvall I, Ingvar C, Isacsson S, Killander D, Jonsson PE, Landberg T, Loven I, Malmport B et al.) 1996 Randomised trial of two versus five years of adjuvant tamoxifen for postmenopausal early stage breast cancer. Journal of the National Cancer Institute 88 1543-1549.
31. Skidmore J, Walpole AL & Woodburn J 1972 Effect of some tripheny lethylenes on oestradiol binding in vitro to macromolecules from uterus and anterior pituitary. Journal of Endocrinology 52 289-298.
32. Stewart HJ 1992 The Scottish trial of adjuvant tamoxifen in node-negative breast cancer. Scottish Cancer Trials Breast Group. Journal of the National Cancer Institute Monographs 117-120.
33. Stewart HJ, Forrest AP, Everington D, McDonald CC, Dewar JA, Hawkins RA, Prescott RJ & George WD 1996 Randomised comparison of 5 years of adjuvant tamoxifen with continuous therapy for operable breast cancer. The Scottish Cancer Trials Breast Group. British Journal of Cancer 74 297-299.
34. Tormey DC, Gray R & Falkson HC 1996 Postchemotherapy adjuvant tamoxifen therapy beyond five years in patients with lymph node-positive breast cancer. Journal of the National Cancer Institute 88 1828-1833.
35. Wood WC 1994 Current trials and future directions of the Eastern Cooperative Oncology Group Breast Cancer Committee. Cancer 74 1132-1134.